Tyk API Management v2.3
Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE!
London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform.
Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove the choice of new functions and features.
The Tyk Gateway can now handle more than twice the traffic of the previous version. It’s more efficient in how it handles Redis, and it’s more clever in how it manages traffic.
To extend the functionality that comes out of the box, rich plugins now make it possible to write powerful and performant middleware in whatever language you prefer.
Plugins can now be written in many languages including Python, Lua, gRPC, C++, Java, Ruby and C#.
As open-source advocates, Tyk encourages community developed plugins, in addition to those provided by the Tyk team.
The first open source API Management platform designed for the needs of micro-service architectures and optimised for the New Stack.
Tyk’s aim is to make managing APIs simple, cost effective, and trivial. They now have thousands of users and customers around the world from major Fortune 500 corporations to innovative startups as well as a thriving open-source community who contribute to the product.
For more information please visit https://tyk.io
Tyk Technologies Ltd
31 Charlotte Road
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tyk API Management v2.3 here
News-ID: 393837 • Views: 3450
More Releases for API
Terminating Twitter API Integrations
Thexyz Inc, the leading private email service that protects people and their data announces that a Twitter authentication apps developed by Thexyz will be discontinued and no longer supported. Thexyz focuses on security, privacy, freedom, and an open internet that respects the rights of individuals. It is a goal to work with organizations that share these values and discontinue support for services that do not. Thexyz has developed applications
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The
Global Biotech API Market Analysis
RNCOS has recently added a new Market Research Report titled, “Global Biotech API Market Analysis” to its report gallery. Biotech APIs contribute a very low share in the global API market with synthetic API’s accounting for majority of the formulations. However, with the revolutionary growth in the biopharmaceutical industry and gaining applications of biotech drugs, biotech API’s are sure to see a highly prospective market in the future. As per our